Terms: = Ovarian cancer AND PRF1, P14222, PFP, P1, MGC65093, HPLH2, FLH2, ENSG00000180644, 5551 AND Diagnosis
11 results:
1. Posterior pelvic exenteration for ovarian cancer: surgical and oncological outcomes.
Houvenaeghel G; de Nonneville A; Blache G; Buttarelli M; Jauffret C; Mokart D; Sabiani L
J Gynecol Oncol; 2022 May; 33(3):e31. PubMed ID: 35320883
[TBL] [Abstract] [Full Text] [Related]
2. P1 promoter IGF-1 polymorphism and IGF-1, IGF-R, LSF, and TSG 101 expression profile in endometriosis.
Kwasniewski W; Stupak A; Wolun-Cholewa M; Fronczek A; Kwasniewska A; Kotarski J; Polak G; Gozdzicka-Jozefiak A
Ginekol Pol; 2022; 93(10):775-786. PubMed ID: 35072229
[TBL] [Abstract] [Full Text] [Related]
3. Meta-analysis identifying epithelial-derived transcriptomes predicts poor clinical outcome and immune infiltrations in ovarian cancer.
Li DF; Tulahong A; Uddin MN; Zhao H; Zhang H
Math Biosci Eng; 2021 Jul; 18(5):6527-6551. PubMed ID: 34517544
[TBL] [Abstract] [Full Text] [Related]
4. A label-free pfp-based photoelectrochemical biosensor for highly sensitive detection of PARP-1 activity.
Wang C; Li Y; Xu E; Zhou Q; Chen J; Wei W; Liu Y; Liu S
Biosens Bioelectron; 2019 Aug; 138():111308. PubMed ID: 31103013
[TBL] [Abstract] [Full Text] [Related]
5. A multifunctional-targeted nanoagent for dual-mode image-guided therapeutic effects on ovarian cancer cells.
Chen C; Sun J; Chen S; Liu Y; Zhu S; Wang Z; Chang S
Int J Nanomedicine; 2019; 14():753-769. PubMed ID: 30718954
[TBL] [Abstract] [Full Text] [Related]
6. Low-intensity focused ultrasound (LIFU)-activated nanodroplets as a theranostic agent for noninvasive cancer molecular imaging and drug delivery.
Liu J; Xu F; Huang J; Xu J; Liu Y; Yao Y; Ao M; Li A; Hao L; Cao Y; Hu Z; Ran H; Wang Z; Li P
Biomater Sci; 2018 Nov; 6(11):2838-2849. PubMed ID: 30229771
[TBL] [Abstract] [Full Text] [Related]
7. Serum antiglycan antibody detection of nonmucinous ovarian cancers by using a printed glycan array.
Jacob F; Goldstein DR; Bovin NV; Pochechueva T; Spengler M; Caduff R; Fink D; Vuskovic MI; Huflejt ME; Heinzelmann-Schwarz V
Int J Cancer; 2012 Jan; 130(1):138-46. PubMed ID: 21351089
[TBL] [Abstract] [Full Text] [Related]
8. Rupture of a malignant ovarian tumor in pregnancy presenting as acute abdomen.
Malhotra N; Sumana G; Singh A; Deka D; Mittal S
Arch Gynecol Obstet; 2010 May; 281(5):959-61. PubMed ID: 19949808
[TBL] [Abstract] [Full Text] [Related]
9. Expression of hepatocyte nuclear factor 4 alpha in primary ovarian mucinous tumors.
Sugai M; Umezu H; Yamamoto T; Jiang S; Iwanari H; Tanaka T; Hamakubo T; Kodama T; Naito M
Pathol Int; 2008 Nov; 58(11):681-6. PubMed ID: 18844932
[TBL] [Abstract] [Full Text] [Related]
10. Insulin-like growth factor binding protein-3 (IGFBP-3) acts as an invasion-metastasis suppressor in ovarian endometrioid carcinoma.
Torng PL; Lee YC; Huang CY; Ye JH; Lin YS; Chu YW; Huang SC; Cohen P; Wu CW; Lin CT
Oncogene; 2008 Apr; 27(15):2137-47. PubMed ID: 17952116
[TBL] [Abstract] [Full Text] [Related]
11. Transdominant DeltaTAp73 isoforms are frequently up-regulated in ovarian cancer. Evidence for their role as epigenetic p53 inhibitors in vivo.
Concin N; Becker K; Slade N; Erster S; Mueller-Holzner E; Ulmer H; Daxenbichler G; Zeimet A; Zeillinger R; Marth C; Moll UM
Cancer Res; 2004 Apr; 64(7):2449-60. PubMed ID: 15059898
[TBL] [Abstract] [Full Text] [Related]
